Heat Biologics COVID-19 vaccine shows encouraging action in preclinical study
Jul. 29, 2020 7:59 AMHeat Biologics, Inc. (HTBX)By: Douglas W. House, SA News Editor
Heat Biologics (NASDAQ:HTBX) announces results from preclinical testing of its COVID-19 vaccine candidate
daniberar
Posts
-
-
Week hands will sell, I’m not selling especially that are a few days until august when will be the vaccine ready
-
It’s a good stock with big potential, and august PR is coming soon, Heat Biologics Inc (HTBX) stock is higher by 1.99% while the S&P 500 is unmoved 0% as of 9:59 AM on Monday, Jul 27. HTBX is higher by $0.05 from the previous closing price of $2.51 on volume of 3,636,925 shares. Over the past year the S&P 500 has risen 6.44% while HTBX is higher by 392.31%. HTBX lost -$0.54 per share in the over the last 12 months
-
Analyst's Opinion
Consensus Rating
Heat Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Heat Biologics has a potential upside of 131.5% from its current price of $2.16. -
This stock will be the next Moderna , but they will find the good vaccine for COVID-19
-
Is going to 3$ today UP UP UP
-
The EPS of TNXP is strolling at -68.54, measuring its EPS growth this year at 92.8%. As a result, the company has an EPS growth of 34.4% for the approaching year
-
The EPS of TNXP is strolling at -68.54, measuring its EPS growth this year at 92.8%. As a result, the company has an EPS growth of 34.4% for the approaching year.
-
Read the stock master NEWS about SNSS, to see why is going up,
-
BIG Potential , it will grow soon. https://www.investorsobserver.com/news/stock-update/should-oragenics-inc-ogen-stock-be-in-your-portfolio
HTBX
HTBX
HTBX
HTBX
HTBX
TNXP
TNXP
HTBX
HTBX
HTBX
TNXP
TNXP
TNXP
SNSS
SNSS
OGEN
SNSS
SNSS
GE
OGEN